Announced
Synopsis
The Blackstone Group agreed to invest $337m in Medtronic, a medical device company. The investment is aimed at advancing new, innovative products especially designed to reduce the burden of diabetes management. "This collaboration, our first investment in the medical devices space, demonstrates how Blackstone Life Sciences is using its capital and expertise to help bring vital technologies, with the potential to save lives, to patients who need them. We look forward to partnering with Medtronic, the leader in this space, to advance their next generation of innovative medical devices for diabetes patients," Nicholas Galakatos, Blackstone Life Sciences Global Head.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.